Skip to main content
v2026.11,986 entries · CC-BY 4.0

RARF (CASRAI)

Regulatory Affairs Course for Research Sites: Foundation, RARF (CASRAI)

Self-paced course and exam for research sites: IND and IDE questions, FDA forms, consent and IRB rules, site reporting, and ClinicalTrials.gov. 50 questions, 70% pass.

LevelFoundationRARRARF (CASRAI)
3 h
Nominal
Self-paced study
7
Lessons
Self-paced
6
Domains
Exam blueprint
50
Exam items
Per attempt
70%
Pass mark
Fixed, uncurved
90
Retake wait
Days
3 yr
Valid for
From the pass

What you earn

The credential itself

Pass the examination and CASRAI issues this certificate and the post-nominal RARF (CASRAI), signed by the Programme Director, valid for 3 years, and checkable by anyone from the verification code on its face.

Specimen. Issued as a signed PDF and as a machine-readable Open Badge; the holder and code shown are illustrative.
How it appears on your CV

Certifications

RARF (CASRAI) — Regulatory Affairs for Research Sites, Foundation

CASRAI·Issued Mar 2026·Credential ID CASRAI-RAR-2026-AA0601

casrai.org/verify/CASRAI-RAR-2026-AA0601

Every certificate is issued under the signature of Dr. Diana Nieves Castro, MD, Programme Director of CASRAI Certification, who sets the syllabus, blueprint and pass mark for this credential.

It certifies that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published on this page — and anyone can confirm it from the verification code, without an account and without contacting us.

About this credential

What it covers

CASRAI Certificate in Regulatory Affairs for Research Sites (Foundation), RARF (CASRAI). A self-paced online course and examination on the US regulatory obligations that fall on academic research sites and sponsor-investigators: whether a study needs an IND or an IDE, the FDA forms, the consent and IRB rules under FDA’s regulations and the Common Rule, site reporting and records, and ClinicalTrials.gov registration. Each module starts from the text of the regulation in the eCFR.

Who it is for

  • Site regulatory coordinators and regulatory specialists
  • Study coordinators who maintain the regulatory binder, collect Forms FDA 1572 and CVs, and track IRB submissions
  • Research administrators and clinical trials office staff who are asked “does this need an IND?”
  • IRB staff and members who must decide whether a study is FDA-regulated
  • Investigators and subinvestigators who sign FDA forms, and academic sponsor-investigators in their first study
  • Research pharmacy, device and imaging staff, and sponsor or CRO start-up staff who work with sites

If your career is in industry regulatory affairs (marketing applications, global submission strategy, product lifecycle), the RAPS credentials are built for that work and this course is not a substitute for them. RARF (CASRAI) is not the RAPS Regulatory Affairs Certification (RAC) or Foundation in Regulatory Affairs (FRA) and is not equivalent to either.

What you will be able to do

  • Classify a study as FDA-regulated, covered by the Common Rule, both or neither, and identify the sponsor, investigator and any sponsor-investigator under 21 CFR 312.3 and 812.3.
  • Apply the five conditions of 21 CFR 312.2(b)(1) to a study of a marketed drug, tell the exemption apart from the practice of medicine under § 312.2(d), and explain why an IND cannot be filed “to be safe” for an exempt study.
  • Apply the significant risk device definition in 21 CFR 812.3(m) and explain what a non-significant risk study still owes under § 812.2(b).
  • Match Forms FDA 1571, 1572, 3454 and 3455 to their signers and regulations, list what Form 1572 must contain, and recognise that a device study uses the § 812.43(c) investigator agreement instead.
  • Compare the consent and IRB requirements of 21 CFR Parts 50 and 56 with 45 CFR 46, including continuing review, consent documentation, the minimal-risk waiver in § 50.22 and the emergency provisions in §§ 50.23 and 50.24.
  • Assign the right party, clock and citation to investigator safety reports and records under Parts 312 and 812, and decide whether a trial is an applicable clinical trial under 42 CFR Part 11, who the responsible party is, and when it must be registered and its results reported.

The seven modules

  1. Which rules apply, and to whom. FDA’s regulations and the Common Rule, when each applies, the sponsor and investigator roles, and an orientation to the EU and UK clinical trial rules and ICH E6(R3).
  2. The IND question. The IND exemption for marketed drugs, condition by condition, the other exemptions, and the cases that always need an IND.
  3. The IDE question and the risk determination. Significant and non-significant risk devices, the abbreviated requirements, and the exempted device investigations.
  4. The regulatory file and the four forms. Forms FDA 1571, 1572, 3454 and 3455, the device investigator agreement, financial disclosure, and essential records.
  5. Consent and the IRB, under two regimes. Consent elements, documentation, waivers and emergency exceptions, continuing review and multi-site review under FDA’s rules and the Common Rule.
  6. Reporting, records and retention. Investigator safety reports for drugs and devices, case histories, control of the investigational product, and record retention.
  7. Registration and results. Applicable clinical trials, the responsible party, registration and results deadlines, the consequences of not submitting, and an orientation to CTIS in the EU.

The examination

  • 50 scored four-option questions per attempt, drawn from a larger question bank in proportion to the six examination domains: regulatory framework and roles 16%; IND and IDE determinations 22%; the regulatory file and FDA forms 20%; consent and IRB rules 18%; reporting and records 14%; registration and results 10%.
  • Most questions describe a short situation at a site and ask you to apply the rule; the rest test knowledge you need to recognise without looking it up.
  • Pass mark: 70%.
  • Must be finished within 4 hours of starting.
  • You must complete all lessons before you can start the examination.
  • If you do not pass, you can retake the examination after 90 days.

Eligibility

Foundation has no prerequisites: there is no experience or education requirement.

The Professional tier, RARP (CASRAI), is for people with regulatory responsibility. A Professional candidate confirms at checkout that they meet one of three routes: 24 months of full-time-equivalent experience in a role carrying regulatory responsibility for clinical research within the last 6 years; or a degree or diploma in a health, life-science, pharmacy, nursing, law or regulatory-science discipline plus 12 months of that experience; or RARF (CASRAI) plus 12 months of that experience. The confirmation is a self-attestation; no documents are checked.

What the credential is, and what it is not

RARF (CASRAI) is an examined credential issued by CASRAI. It shows that you passed an examination built to the modules and domain weights set out on this page, and it can be verified.

  • It is not accredited by any accreditation body.
  • It carries no continuing education credit (no CE, CME or CEU).
  • It does not satisfy any statutory, regulatory, funder, sponsor, employer or institutional training requirement.
  • It is not issued, endorsed or recognised by FDA, HHS, EMA, the MHRA, RAPS or any other regulator, funder or professional body.
  • It gives no authority to decide that a study is exempt from the IND requirements, that a device is not a significant risk device, or that a trial is not an applicable clinical trial. Those determinations belong to the sponsor, the IRB or FDA, as the regulations say, and the course teaches exactly that.
  • The designation is always written with its parenthetical: RARF (CASRAI).

Validity and renewal

The certificate is valid for 3 years from the date you pass. To renew it, you pass the current version of the examination again.

Price and access

US$119, paid once. Your access to the course does not expire.

Body of knowledge

Exam blueprint

The exam is assembled to these weights on every attempt. They are published before purchase because a blueprint you cannot see is not a blueprint.

Domains and weights6 domains · 50 scored items
DomainWeight
The regulatory framework and who is whoF1
16%8 items
Does this study need an IND or an IDE?F2
22%11 items
The regulatory file and the FDA formsF3
20%10 items
Consent and IRB rules at the siteF4
18%9 items
Reporting and record obligations at the siteF5
14%7 items
Trial registration and results disclosureF6
10%5 items
Total100%

Every attempt has this many items from each domain. The items themselves are drawn at random from the bank within those fixed per-domain quotas, so no two attempts are the same paper.

Syllabus

Syllabus: 7 lessons, 3 hours

Every lesson and every learning outcome is listed. The lesson bodies open on enrolment, and the exam opens once every lesson is marked complete.

7 lessons · 3.3 h

Lesson material opens once you are enrolled. The full syllabus and every learning outcome are shown here so you can judge the coverage before you pay.

  1. Lesson 1

    Module 1

    1 lesson · 30 min

    1. Locked.Which rules apply, and to whom30 min · Locked

      On completion you will be able to

      • Classify a described study as FDA-regulated, Common-Rule-covered, both or neither, and state the provision that decides it.
      • Identify the sponsor, investigator, subinvestigators and any sponsor-investigator in a described arrangement, citing 21 CFR 312.3 or 812.3.
      • Name the CFR part that governs a described question (consent, IRB review, financial disclosure, drugs, devices, registration).
      • Compare the vulnerable-population wording of 21 CFR 56.111 and 45 CFR 46.111 and explain why a single unqualified statement is wrong.
      • State the current status of the EU Clinical Trials Regulation and CTIS, the UK 2025 amending regulations and ICH E6(R3) in the EU and at FDA.
  2. Lesson 2

    Module 2

    1 lesson · 30 min

    1. Locked.The IND question: exemptions and when an IND is required30 min · Locked

      On completion you will be able to

      • State the five conditions of 21 CFR 312.2(b)(1) and explain that all five must hold.
      • Apply the five conditions to a described study of a marketed drug and identify the condition in issue.
      • Distinguish the § 312.2(b)(1) exemption from the § 312.2(d) practice-of-medicine provision in a described case.
      • Explain the effect of § 312.2(b)(4) on defensive filing and identify § 312.2(e) advice as the route when the answer is unclear.
      • Identify situations that need an IND despite marketed status, including emergency research under § 50.24 (§ 312.2(b)(6), § 312.20(c)).
      • Write a short escalation note stating the unresolved condition and the facts needed to resolve it.
  3. Lesson 3

    Module 3

    1 lesson · 30 min

    1. Locked.The IDE question and the risk determination30 min · Locked

      On completion you will be able to

      • Apply each limb of 21 CFR 812.3(m) to a described device and identify the second finding that limbs (1) to (3) require.
      • Explain the abbreviated requirements of § 812.2(b)(1) and state that no application goes to FDA unless FDA requires one.
      • Identify the § 812.2(c) exempted categories and apply the four-part diagnostic device test, using the § 812.3(k) definition.
      • Distinguish a significant risk determination from a minimal risk determination and state what each one decides.
      • Describe what happens under §§ 812.66 and 812.30(a) when the IRB finds a device significant risk.
  4. Lesson 4

    Module 4

    1 lesson · 30 min

    1. Locked.The regulatory file and the four forms30 min · Locked

      On completion you will be able to

      • Identify Forms FDA 1571, 1572, 3454 and 3455 by purpose, signer and governing regulation.
      • List the contents of Form FDA 1572 required by § 312.53(c)(1) and spot an omission in a described form.
      • Explain why Form FDA 1572 does not apply to a device study and describe the § 812.43(c) investigator agreement, including where its financial information is submitted.
      • Apply the Part 54 definition of clinical investigator and the equity and payment thresholds to a described study team.
      • Audit a described regulatory file, separating regulatory findings from sponsor or institutional practice.
  5. Lesson 5

    Module 5

    1 lesson · 30 min

    1. Locked.Consent and the IRB, under two regimes30 min · Locked

      On completion you will be able to

      • Compare the consent elements of 21 CFR 50.25 with 45 CFR 46.116 and identify what an FDA-regulated consent form must add.
      • Apply the § 50.27(a) documentation requirement to a described consent form.
      • Distinguish §§ 50.22, 50.23 and 50.24 and identify which governs a described situation.
      • State the FDA continuing review requirement and explain why the Common Rule relief in 45 CFR 46.109(f) does not reach FDA-regulated research.
      • State the IRB review position for multi-site research under 21 CFR 56.114 and 45 CFR 46.114.
  6. Lesson 6

    Module 6

    1 lesson · 30 min

    1. Locked.Reporting, records and retention30 min · Locked

      On completion you will be able to

      • Apply § 312.64(b) to a described serious adverse event, including the study-endpoint provision.
      • Distinguish the investigator's 'immediately' from the sponsor's 15- and 7-calendar-day clocks and state the event each runs from.
      • Assign the correct recipient and clock to a described device event under § 812.150(a).
      • State the retention rules in § 312.62(c) and § 812.140(d) and apply them to a described study.
      • Identify when an investigator may and may not supply an investigational drug under § 312.61.
  7. Lesson 7

    Module 7

    1 lesson · 15 min

    1. Locked.Registration and results on ClinicalTrials.gov15 min · Locked

      On completion you will be able to

      • Determine whether a described trial is an applicable clinical trial under 42 CFR 11.10(a) and 11.22(b).
      • Identify the responsible party for a described trial and test a proposed PI designation against § 11.4(c)(2).
      • State the § 11.24 registration and § 11.44 results deadlines and calculate them for a described trial.
      • Describe the consequences in § 11.66 of failing to submit required information.
      • Explain why ClinicalTrials.gov registration does not replace an EU application through CTIS.

Assessment

How the exam works

The exam is closed-book and multiple choice. Each attempt draws a fresh form to the domain weights above, so no two attempts are the same paper and no answer key circulates. The pass mark is 70% and is fixed — there is no curve, no quota and no adjustment by cohort.

Scoring is immediate. Pass, and every item is reviewed with the option you chose, the correct option and its rationale. If you do not pass, you see your overall score and your score per domain (smaller domains are grouped together); which items you missed, and their answers, are held back so your resit is still a real assessment. A failed attempt may be retaken after 90 days. The wait exists so a retake is a second attempt at the material rather than a second attempt at remembering the paper.

The exam opens once you have marked every lesson of the course complete. Forms are assembled to the blueprint above or not at all: where a domain cannot yet be sampled to that standard, the exam declines to start rather than issue an unbalanced paper. Your material and progress are never affected, and there is no time limit on when you sit.

Passing candidates are issued a certificate with a verification code, valid for 3 years from the date of the pass. Anyone can check that code on our public verification page without an account and without contacting us. To renew, pass the current examination again: renewal opens 180 days before the certificate expires, and a pass issues a renewed certificate valid for a further 3 years from that date.

Certifying authority

Signed by Dr. Diana Nieves Castro, MD

CASRAI’s certification programme is academically and medically directed by Dr. Diana Nieves Castro, MD, Programme Director, who sets the syllabus and blueprint for this credential and signs every certificate issued under it.

CASRAI has maintained the terminology and reporting standards of research administration for over a decade. It assumed leadership of the CRediT contributor-roles taxonomy in 2014 and carried it through to adoption as ANSI/NISO Z39.104-2022, now in use by publishers, funders and institutions worldwide. This examination is drawn from that body of work.

What the credential certifies: that its holder passed the CASRAI examination for this course on the date shown, scored against the blueprint and pass mark published above. It is valid for 3 years, and anyone can check it from the verification code on its face.

The ladder

Other levels of Regulatory Affairs for Research Sites

Levels are independent purchases. There is no prerequisite chain — sit whichever level matches the work you already do.

All CASRAI credentials

Common questions

Regulatory Affairs Course for Research Sites: Foundation, RARF (CASRAI): common questions

Which regulatory affairs course should I take?

It depends on where you work. This course is for people at academic research sites and in sponsor-investigator roles: whether a study needs an IND or an IDE, the FDA forms, consent and IRB rules, site reporting and records, and ClinicalTrials.gov registration. If your career is in industry regulatory affairs, such as marketing applications and global submission strategy, an industry-focused programme fits better; RARF (CASRAI) is not endorsed by RAPS, FDA or any other body.

How long does it take to get regulatory affairs certification?

The Foundation course has seven lessons and 3 hours of study, worked through at your own pace. After completing all lessons you take a 50-question online multiple-choice exam, which must be finished within 4 hours of starting. The pass mark is 70%, and after a failed attempt you can retake the exam after a 90-day waiting period.

How much does a regulatory affairs course cost?

The Foundation course and exam cost US$119, a one-time card payment through Stripe checkout. Course access does not expire.

Can I take a regulatory affairs course for free?

Free material exists, including the federal regulations themselves, which anyone can read in the eCFR. This course is paid because it ends in an examined credential, RARF (CASRAI), with a public verification page for each certificate. It carries no CE credits, is not accredited and does not satisfy any employer, IRB or funder training requirement.

What does a clinical research regulatory coordinator do?

At a research site the regulatory coordinator typically maintains the regulatory binder, collects Forms FDA 1572 and investigator CVs, and tracks IRB submissions. The Foundation course is written for site regulatory coordinators and specialists, study coordinators and others who handle regulatory documents, and it has no experience prerequisite. Passing does not give anyone authority to decide that a study is IND-exempt; that determination belongs to the sponsor, the IRB or FDA.

How long is the certificate valid?

The certificate is valid for 3 years. You renew it by passing the current exam again, and the renewal window opens 180 days before expiry. Each certificate can be checked on a public verification page at casrai.org/verify.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →